Deerfield Management Company, L.P. (Series C) Replimune Group, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.01 - $9.46 $3.88 Million - $7.32 Million	-773,684 Reduced 96.35%	29,300 $263,000
Q1 2024 May 15, 2024	SELL	$6.87 - $9.31 $6.93 Million - $9.39 Million	-1,008,726 Reduced 55.68%	802,984 $6.56 Million
Q4 2023 Feb 14, 2024	BUY	$6.75 - $16.18 $12.2 Million - $29.3 Million	1,811,710 New	1,811,710 $15.3 Million

Others Institutions Holding REPL

# of Institutions

149

Shares Held

68M

Call Options Held

52.3K

Put Options Held

80.3K

Baker Bros. Advisors LP New York, NY

11M
Shares

$138 Million
1.3% of portfolio
Price T Rowe Associates Inc Baltimore, MD

9.88M
Shares

$123 Million
0.01% of portfolio
Fcpm Iii Services B.V. Naarden, P7

4.87M
Shares

$60.8 Million
9.16% of portfolio
Redmile Group, LLC San Francisco, CA

4.78M
Shares

$59.8 Million
3.43% of portfolio
Black Rock Inc. New York, NY

4.71M
Shares

$58.9 Million
0.0% of portfolio

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $616M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account